5611 - 5620 of 6256 Results
Title
Year
- Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model2022OPENTitle: Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse modelJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 218Issue #:Start Page: 109213End Page: 109213Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.109213Best OA location URL: https://doi.org/10.1016/j.neuropharm.2022.109213Citation Count: 8
-
OPENTitle: Special Issue on new therapeutic approaches to Parkinson diseaseJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 208Issue #:Start Page: 108998End Page: 108998Publication Date:Open Access(OA) Status: OPENLicense: other-oaDOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.108998Best OA location URL: https://doi.org/10.1016/j.neuropharm.2022.108998Citation Count: 4
-
OPENTitle: Preserved motor memory in Parkinson's diseaseJournal Name: NeuropsychologiaPublisher: Elsevier BVVol: 167Issue #:Start Page: 108161End Page: 108161Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neuropsychologia.2022.108161Best OA location URL: https://doi.org/10.1101/2021.04.30.441882Citation Count: 13
- Necessity and feasibility of remote tele-programming of deep brain stimulation systems in Parkinson's disease2022OPENTitle: Necessity and feasibility of remote tele-programming of deep brain stimulation systems in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 96Issue #:Start Page: 38End Page: 42Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.01.017Best OA location URL: https://doi.org/10.1016/j.parkreldis.2022.01.017Citation Count: 25
- Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies2022OPENTitle: Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studiesJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 96Issue #:Start Page: 65End Page: 73Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.01.022Best OA location URL: https://doi.org/10.1016/j.parkreldis.2022.01.022Citation Count: 18
- Perivascular space in Parkinson's disease: Association with CSF amyloid/tau and cognitive decline2022OPENTitle: Perivascular space in Parkinson's disease: Association with CSF amyloid/tau and cognitive declineJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 95Issue #:Start Page: 70End Page: 76Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.01.002Citation Count: 28
- Stimulation of the pedunculopontine and cuneiform nuclei for freezing of gait and falls in Parkinson disease: Cross-over single-blinded study and long-term follow-up2022OPENTitle: Stimulation of the pedunculopontine and cuneiform nuclei for freezing of gait and falls in Parkinson disease: Cross-over single-blinded study and long-term follow-upJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 96Issue #:Start Page: 13End Page: 17Publication Date:Open Access(OA) Status: OPENLicense: other-oaDOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.01.010Best OA location URL: https://hal.sorbonne-universite.fr/hal-03603648Citation Count: 15
- Polygenic burden of Parkinson's disease risk stratifies the prognosis of isolated rapid-eye-movement disorder: A preliminary observational study2022OPENTitle: Polygenic burden of Parkinson's disease risk stratifies the prognosis of isolated rapid-eye-movement disorder: A preliminary observational studyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 96Issue #:Start Page: 52End Page: 56Publication Date:Open Access(OA) Status: OPENLicense: other-oaDOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.02.005Best OA location URL: https://doi.org/10.1016/j.parkreldis.2022.02.005Citation Count: 2
- Characterization and diagnostic potential of R2* in early-stage progressive supranuclear palsy variants2022OPENTitle: Characterization and diagnostic potential of R2* in early-stage progressive supranuclear palsy variantsJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 101Issue #:Start Page: 43End Page: 48Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.06.021Best OA location URL: http://www.prd-journal.com/article/S1353802022002176/pdfCitation Count: 10
-
OPENTitle: What the VaP? The meaning of “vascular parkinsonism”Journal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 94Issue #:Start Page: 132End Page: 134Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.12.008Best OA location URL: http://www.prd-journal.com/article/S1353802021004636/pdfCitation Count: 7